Navigation Links
Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells
Date:4/16/2008

LOS ANGELES (April 15, 2008) A common, naturally occurring virus that attacks cancer cells but appears to be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive and deadly brain tumors called gliomas. Researchers at Cedars-Sinai Medical Center are among a few in the United States evaluating this experimental therapy.

Over the course of a lifetime, most adults will be exposed to the virus in its natural state. It commonly infects the lungs and intestines but unlike most viruses causes few if any symptoms and is usually eliminated by the body within two weeks. But while the reovirus (respiratory enteric orphan virus) may be harmless to normal cells, it can specifically kill certain cancer cells.

Vulnerable cancer cells have a defect in a signaling pathway (the Ras pathway) that controls key cell functions. The reovirus is able to infect and kill cancer cells that have an activated Ras pathway, but the virus does not normally come into contact with cancer cells. Researchers at Oncolytics Biotech Inc., of Calgary, Canada, developed a therapeutic drug, REOLYSIN, from the reovirus and are conducting multicenter clinical trials for a variety of cancers. Cedars-Sinai is participating only in the study on recurrent gliomas, the most common and deadly brain cancers.

Based on the fact that many types of cancer cells have an activated Ras pathway, the company estimates that up to two thirds of all human cancers are susceptible to reovirus induced cell death .

Although not every glioma cell line has an activated Ras pathway, Ras activation is very common in these malignant brain cancers. In lab tests and animal studies, the reovirus appears to target Ras-activated tumor cells and leave normal cells alone, said neurosurgeon John S. Yu, M.D., director of Surgical Neuro-oncology at Cedars-Sinais Department of Neurosurgery. Yu is principal investigator of the REOLYSIN clinical trial at Cedars-Sinai.

According to the protocol of this open-label Phase I and II trial, patients will receive a single treatment of REOLYSIN, infused over 72 hours and directed into the tumor under sophisticated guidance. Expected length of hospital stay is about five days, and patients progress will be followed for at least 12 weeks.

Oncolytics published results of preclinical studies in the June 20, 2001 issue of the Journal of the National Cancer Institute. In an animal study, mice with gliomas that were treated with a single injection of reovirus survived significantly longer than untreated mice. Complete tumor regression was found in 20 of 23 mice treated with the virus.

In laboratory studies, widespread cell killing was seen in 19 of 24 established human glioma cell lines tested. Reovirus also infected and killed all nine of nine primary glioma cultures taken from brain tumor surgical specimens. Primary refers to gliomas originating in the brain, not metastasizing from other locations.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
800-880-2397
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
2. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
3. Roseland Medical Center Hosts Recognition Ceremony and Open House
4. Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations
5. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
6. Health Care Workforce Experts Available to Comment on IOM Report on Aging Baby Boomers and Impending Medical System Crisis
7. HHS Names First Director of the Biomedical Advanced Research Development Authority
8. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
9. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
10. Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... The ... seminar to focus on current legislative activity and the latest regulatory concerns impacting ... p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are sure ... , “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
(Date:5/26/2017)... ... 26, 2017 , ... “When the Stars Lead Home”: a poignant story of ... author Laura Weigel Douglas, an avid reader who lives in the Pacific Northwest with ... like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the story of ... “Cactus Jack: Against All Odds” is the creation of published author, Walter Hubbard, a ... to Jack Carlisle’s third child Jane. Walter. Walter and Jane have three adult ...
Breaking Medicine News(10 mins):
(Date:5/12/2017)... 2017  The China and Canada joint ... less water, energy and detergent, and features a powerful disinfection process. ... shoebox-sized washing machine that washes and sanitizes women,s panties or babies, ... ... and does not require an external water inlet. ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
Breaking Medicine Technology: